@Article{Aruanno2021,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="38",
number="5",
year="2021",
title="Efficacy of omalizumab in reducing latex allergy",
abstract="Omalizumab, a humanized monoclonal antibody that binds the CH3 domain near the binding site for the high affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway [1].  The current indications for treatment with omalizumab are limited to severe persistent allergic asthma and chronic spontaneous urticaria (CSU) when it is not controlled by conventional anti-H1 treatment at the maximum dosage.  In recent years, several studies [1] have shown that omalizumab is effective in a large number of IgE-mediated and non-IgE-mediated disorders, indicating that omalizumab treatment acts on many levels and not only on immunoglobulins E [2].",
author="Aruanno, Arianna
and Chini, Raffaella
and Nucera, Eleonora",
pages="921--923",
doi="10.5114/ada.2021.110072",
url="http://dx.doi.org/10.5114/ada.2021.110072"
}